Table 1 Laboratory and other participant assessments collected
Assessment | Pre-screen | Screen | Baseline (week 0) | Week 4 | End of treatment | 12-week post-treatment | As needed |
|---|---|---|---|---|---|---|---|
Rapid HCV test | X | ||||||
CTP assessment | X | ||||||
Participant survey | X | X | X | X | X | ||
HCV RNA | X | X | |||||
Hepatitis B surface antigen | X | ||||||
Hepatitis B surface antibody | X | ||||||
Hepatitis B core antibody | X | ||||||
Hepatitis A antibody | X | ||||||
HIV antigen/antibody | X | ||||||
Complete metabolic panel | X | X | |||||
Complete blood count | X | X | |||||
INR/prothrombin | X | ||||||
B-HCG (women < 50 only) | X | ||||||
Ultrasound | X | ||||||
HCV genotype (treatment experienced) and resistance testing | X | ||||||
Medication counseling | X | X |